Confronto

Lanreotid vs. Pasireotid

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Ricerca (altro)

N. CAS

108736-35-2

396091-73-9

Peso molecolare

1096.34 g/mol

1047.21 g/mol

Emivita

nessun dato

Sequenza

nessun dato

Meccanismo d'azione

Lanreotid

Lanreotide activates somatostatin receptors (chiefly SSTR2, additionally SSTR5), thereby suppressing the release of growth hormone, IGF-1 and various gastrointestinal and neuroendocrine hormones. It is metabolically far more stable than natural somatostatin.

Pasireotid

Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.

Base di evidenze

Evidenza più alta

RCT sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	Lanreotid	Pasireotid
Germania	Su prescrizione	Su prescrizione
Stati Uniti	Su prescrizione	Su prescrizione

Voci complete

Frequently asked questions

What is the difference between Lanreotid and Pasireotid?: Lanreotid is classified as "Ricerca (altro)", while Pasireotid is classified as "Ricerca (altro)". Lanreotid: Lanreotide is a synthetic cyclic octapeptide analog of somatostatin. It binds preferentially to the somatostatin receptors SSTR2 and SSTR5 and is approved for treating acromegaly and certain neuroendocrine tumours. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Lanreotid or Pasireotid?: The highest available evidence level is "RCT sull'uomo" for Lanreotid and "RCT sull'uomo" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Lanreotid and Pasireotid in Germany and the United States?: Germania: Lanreotid — Su prescrizione, Pasireotid — Su prescrizione. Stati Uniti: Lanreotid — Su prescrizione, Pasireotid — Su prescrizione. These are factual summaries with source and review date on the individual pages.

Country

Lanreotid

Pasireotid

Germania

Su prescrizione

Stati Uniti

Su prescrizione

Frequently asked questions

What is the difference between Lanreotid and Pasireotid?

Lanreotid is classified as "Ricerca (altro)", while Pasireotid is classified as "Ricerca (altro)". Lanreotid: Lanreotide is a synthetic cyclic octapeptide analog of somatostatin. It binds preferentially to the somatostatin receptors SSTR2 and SSTR5 and is approved for treating acromegaly and certain neuroendocrine tumours. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Lanreotid or Pasireotid?

The highest available evidence level is "RCT sull'uomo" for Lanreotid and "RCT sull'uomo" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Lanreotid and Pasireotid in Germany and the United States?

Germania: Lanreotid — Su prescrizione, Pasireotid — Su prescrizione. Stati Uniti: Lanreotid — Su prescrizione, Pasireotid — Su prescrizione. These are factual summaries with source and review date on the individual pages.